GU Cancers 2020 | JAVELIN Renal 101: DepOR & outcomes in RCC

VJOncology is committed to improving our service to you

Martin Voss

Martin Voss, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the depth of response (DepOR) analysis from the JAVELIN Renal 101 trial (NCT02684006), and the correlation with clinical outcomes in renal cell cancer (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter